Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
This article was originally published in The Pink Sheet Daily
Executive Summary
Discontinuation is unrelated to prior safety suspension, say Amylin and Takeda, who acknowledge that "this is a difficult time for innovators and regulators."